High bone mass disorders:​ new insights from connecting the clinic and the bench

Bergen, Dylan J. M.; Maurizi, Antonio; Formosa, Melissa M.; McDonald, Georgina L. K.; El-Gazzar, Ahmed; Hassan, Neelam; Brandi, Maria-Luisa; Riancho, José A.; Rivadeneira, Fernando; Ntzani, Evangelia; Duncan, Emma L.; Gregson, Celia L.; Kiel, Douglas P.; Zillikens, M. Carola; Sangiorgi, Luca; Högler, Wolfgang; Duran, Ivan; Mäkitie, Outi; Van Hul, Wim; Hendrickx, Gretl

Affiliations

¹School of Physiology, Pharmacology, and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK

²Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK

³Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

⁴Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta

⁵Center for Molecular Medicine and Biobanking, University of Malta, Msida, Malta

⁶Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria

⁷Italian Bone Disease Research Foundation (FIRMO), Florence, Italy

⁸Department of Internal Medicine, Hospital U M Valdecilla, University of Cantabria, IDIVAL, Santander, Spain

⁹Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

¹⁰Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina, Greece

¹¹Center for Evidence Synthesis in Health, Policy and Practice, Center for Research Synthesis in Health, School of Public Health, Brown University, Providence, RI, USA

¹²Institute of Biosciences, University Research Center of loannina, University of Ioannina, Ioannina, Greece

¹³Department of Twin Research & Genetic Epidemiology, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK

¹⁴Department of Endocrinology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

¹⁵Marcus Institute for Aging Research, Hebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Broad Institute of MIT & Harvard, Cambridge, MA, USA

¹⁶Department of Rare Skeletal Diseases, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

¹⁷Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

¹⁸University of Malaga, Malaga, Spain

¹⁹Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

²⁰Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland

²¹Folkhälsan Research Centre, Folkhälsan Institute of Genetics, Helsinki, Finland

²²Department of Medical Genetics, University of Antwerp, Antwerp, Belgium

²³Department of Human Genetics, KU Leuven, Leuven, Belgium

Abstract and keywords

Monogenic high bone mass (HBM) disorders are characterized by an increased amount of bone in general, or at specific sites in the skeleton. Here, we describe 59 HBM disorders with 50 known disease-causing genes from the literature, and we provide an overview of the signaling pathways and mechanisms involved in the pathogenesis of these disorders. Based on this, we classify the known HBM genes into HBM (sub)groups according to uniform Gene Ontology (GO) terminology. This classification system may aid in hypothesis generation, for both wet lab experimental design and clinical genetic screening strategies. We discuss how functional genomics can shape discovery of novel HBM genes and/or mechanisms in the future, through implementation of omics assessments in existing and future model systems. Finally, we address strategies to improve gene identification in unsolved HBM cases and highlight the importance for cross-laboratory collaborations encompassing multidisciplinary efforts to transfer knowledge generated at the bench to the clinic.

Keywords: DISEASES AND DISORDERS OF/RELATED TO BONE; ANABOLICS; THERAPEUTICS; GENETIC ANIMAL MODELS; ANIMAL MODELS; CELL/TISSUE SIGNALING; PARACRINE PATHWAYS; GENETIC RESEARCH

Links

DOI: 10.1002/jbmr.4715

PubMed: 36161343

WoS: 000870692100001

History

Received: 2022-05-25

Revised: 2022-09-05

Accepted: 2022-09-22

Cited Works (16)

Year	Entry
2015	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. May 2015;17(5):405-424.
2001	Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo P, Fu Y-H, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan JT. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot–containing protein. Am J Hum Genet. March 2001;68(3):577-589.
2013	Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. September 2013;9(9):522-536.
2022	Xue J-Y, Grigelioniene G, Wang Z, Nishimura G, Iida A, Matsumoto N, Tham E, Miyake N, Ikegawa S, Guo L. SLC4A2 deficiency causes a new type of osteopetrosis. J Bone Miner Res. February 2022;37(2):226-235.
2020	De Ridder R, Boudin E, Zillikens MC, Ibrahim J, van der Eerden BCJ, Van Hul W, Mortier G. A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. Bone. August 2020;137:115406.
2012	Lu XL, Huo B, Chiang V, Guo XE. Osteocytic network is more responsive in calcium signaling than osteoblastic network under fluid flow. J Bone Miner Res. March 2012;27(3):563-574.
2015	Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, Barry KJ, Uda Y, Lai F, Dedic C, Balcells-Camps M, Kronenberg HM, Babij P, Pajevic PD. The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem. July 3, 2015;290(27):16744-16758.
2022	De Kinderen P, Meester J, Loeys B, Peeters S, Gouze E, Woods S, Mortier G, Verstraeten A. Differentiation of induced pluripotent stem cells into chondrocytes: methods and applications for disease modeling and drug discovery. J Bone Miner Res. March 2022;37(3):397-410.
2022	Costantini A, Mäkitie RE, Hartmann MA, Fratzl-Zelman N, Zillikens MC, Kornak U, Søe K, Mäkitie O. Early-onset osteoporosis: rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen. J Bone Miner Res. September 2022;37(9):1623-1641.
2020	Gregson CL, Bergen DJM, Leo P, Sessions RB, Wheeler L, Hartley A, Youlten S, Croucher PI, McInerney‐Leo AM, Fraser W, Tang JCY, Anderson L, Marshall M, Sergot L, Paternoster L, Smith GD, Brown MA, Hammond C, Kemp JP, Tobias JH, Duncan EL; The AOGC Consortium. A rare mutation in SMAD9 associated with high bone mass identifies the SMAD‐dependent BMP signaling pathway as a potential anabolic target for osteoporosis. J Bone Miner Res. January 2020;35(1):92-105.
2022	Kaya S, Schurman CA, Dole NS, Evans DS, Alliston T. Prioritization of genes relevant to bone fragility through the unbiased integration of aging mouse bone transcriptomics and human GWAS analyses. J Bone Miner Res. April 2022;37(4):804-817.
2007	Tan SD, de Vries TJ, Kuijpers-Jagtman AM, Semeins CM, Everts V, Klein-Nulend J. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption. Bone. November 2007;41(5):745-751.
2019	Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, Vulpescu NA, Forgetta V, Kleinman A, Mohanty ST, Sergio CM, Quinn J, Nguyen-Yamamoto L, Luco A-L, Vijay J, Simon M-M, Pramatarova A, Medina-Gomez C, Trajanoska K, Ghirardello EJ, Butterfield NC, Curry KF, Leitch VD, Sparkes PC, Adoum A-T, Mannan NS, Komla-Ebri DSK, Pollard AS, Dewhurst HF, Hassall TAD, Beltejar M-JG; 23andMe Research Team, Adams DJ, Vaillancourt SM, Kaptoge S, Baldock P, Cooper C, Reeve J, Ntzani EE, Evangelou E, Ohlsson C, Karasik D, Rivadeneira F, Kiel DP, Tobias JH, Gregson CL, Harvey NC, Grundberg E, Goltzman D, Adams DJ, Lelliott CJ, Hinds DA, Ackert-Bicknell CL, Hsu Y-H, Maurano MT, Croucher PI, Williams GR, Bassett JHD, Evans DM, Richards JB. An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet. February 2019;51(2):258-266.
2001	Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den J Ende, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. March 1, 2001;10(5):537-543.
2021	Norwood I, Szondi D, Ciocca M, Coudert A, Cohen-Solal M, Rucci N, Teti A, Maurizi A. Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2: preclinical and clinical implications. Bone. March 2021;144:115828.
2021	Dietrich K, Fiedler IAK, Kurzyukova A, López‐Delgado AC, McGowan LM, Geurtzen K, Hammond CL, Busse B, Knopf F. Skeletal biology and disease modeling in zebrafish. J Bone Miner Res. March 2021;36(3):436-458.